Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: A feasibility and pharmacokinetic study

Semilogarithmic plot of systemic and regional (pleural space perfusate). Platinum concentrations versus time in patients with malignant mesothelioma who underwent pleurectomy/decortication and normothermic pleural space perfusion with cisplatin (group A; ●); pleurectomy/decortication and hyperthermic pleural space perfusion with cisplatin (group B; ■); pleuropneumonectomy and hyperthermic pleural space perfusion with cisplatin (group C; ▴).

Microscopic appearance of normal lung parenchyma after pleurectomy/decortication followed by 1 hour of hyperthermic pleural space perfusion with cisplatin. (Hematoxylin-eosin stain; original magnification, ×250.)

CT scan appearance of the lung parenchyma, 3 months (A) and 12 months (B) after pleurectomy/decortication and hyperthermic pleural space perfusion with cisplatin.